DNA Nanobots is a platform biotechnology company with IP-based products and services for improved design and delivery of therapeutics including better targeting and larger payloads. Non-viral gene delivery is our top business area. Nanobots are large, folded DNA nanostructures that enable precision control over the number and spatial locations of targeting antibodies, drug payloads, antigens, and other components for oncology drugs and immunotherapies (cancer vaccines). DNA Nanobots offer major advantages over other delivery solutions. They allow much larger drug payloads than other Antibody-Drug Conjugates (ADCs) and better cell/tissue targeting than lipid nanoparticles (LNPs). Nanobots are stable in vivo and not immunogenic (unless desired). We can engineer our Nanobots with precision to deliver drugs, antigens, siRNAs, mRNAs, genes, peptides, antibodies, biologics, small molecules, etc. to the right cellular targets. DNA Nanobots has good mouse study data showing, for example, improved cancer vaccine responses and better tumor cell killing at lower doses of doxorubicin than free drug or ADC drugs.DNA Nanobots has a pipeline of its own therapeutic products (currently in preclinical animal studies) and diagnostics, but is focusing primarily on partnering with biopharma companies to help them improve performance of their therapeutics.

PanoMatrix is developing a novel activated nanocellulose crystal material isolated from the ivory palm nut. This natural material has amazing properties for wound healing and beauty applications.

Jeff Spitzner serves as founder and CEO of MatchTx, a new Big Data healthcare analytics software company with unique patent-pending technology for the medical industry. The solution enables matching patients to cancer drugs and clinical trials with novel methods to find best matches using genetic, clinical, and outcome data. The tech uses Deep Genetic Signatures (TM) to identify and apply new multi-factor biomarkers that predict outcomes based on reference databases. Spitzner licensed the technology exclusively from partner The Ohio State University.

Amperand provides services and solutions for Technology Business Development, Tech Startups, and Innovation projects, including:- Technology commercialization and tech start-up consulting including assessments, business strategy, product development roadmaps, business planning, market/competitive analysis, fundraising.- Technology Business Management services – including interim senior management roles.- Turnaround/growth services including new products, sales and marketing strategy and implementation.- Informatics and ELN (electronic lab notebook) and other information/data management/software/lab project consulting for R& D organizations.- Due Diligence services for potential corporate acquisitions.- Business Services - strategic partnerships, sales and marketing strategies, company formation, other business development activities.- We work at the intersection of science, business, and technology for clients of all sizes and industries to supply our expertise to help solve problems or grow businesses. We specialize in life sciences, healthcare, information technology, investment, and related disciplines. For lab consulting, Amperand focuses on ‘post-ELN era’ solutions to enable R&D organizations to take advantage of electronic information management to improve business and scientific performance.We are currently working on a number of projects with great companies, including executive management to promote strategic business growth.

We are developing a Noninvasive Deep Brain Stimulation treatment for many diseases in a very cost effective manner. We use a novel form of Noninvasive Deep Brain Stimulation that can target a region deep inside the brain without stimulating the surrounding areas. The Medical Device is not cleared by the FDA for commercial distribution in the United States and is not available for commercial sale. This product is not intended to diagnose, treat, cure, or prevent any disease and is intended for investigational use only.

Better Reporting serves the investment and business communities with agile high quality financial management solutions.

Jeff Spitzner was the business founder of AEIOU Scientific and its CEO from inception through its successful investment fundraising launch and product readiness for scientific sales. The Company was able to prove its scientific instrument in per reviewed publications and achieve FDA Pre-Submission review with only non-dilutive capital. The mission of AEIOU is to improve the targeting of medical care for the prevention of low-trauma fractures. AEIOU is developing and commercializing Ohio University’s patented Cortical Bone Mechanics Technology™ (CBMT) – first as a scientific laboratory instrument, and then later as a non-invasive medical device to be approved by FDA for improving the diagnosis and monitoring of osteoporosis and other bone diseases. The tech has been tested extensively and uniquely provides accurate information about the total strength of bone in vivo.

Signet Innovations focuses on licensing and commercializing technology and IP from universities and research institutions to create new companies and bring new products to market. Signet Accel is the premiere company in the Innovations portfolio. Signet Innovations is building an active portfolio in strategic sectors and looks for technologies and early stage companies with substantial growth opportunities and synergies within its portfolio.Verticals of interest include healthcare/life sciences IT (software), healthcare technologies, energy, materials, engineering, and life sciences. Innovations is a Signet Enterprises company. The Signet parent is a private equity company that currently has over $4 Billion of active projects, ranging from real estate development for health and education systems to a diverse portfolio of over 25 companies that were acquired by Signet, to Integrated Wellness partners and Signet Accel.My role is to find great opportunities, lead the due diligence efforts, perform business development activities, and build bridges between business and technology in order to develop business plans that enable creation of exceptional companies.

Ohio Telehealth Initiative (OTI) is a non-profit organization formed to promote and raise awareness for telehealth solutions to improve the quality and efficiency of healthcare while lowering costs and risks and improving patients' experiences. OTI works with leading healthcare organizations in the State of Ohio to study, educate, implement, and train on the use of telehealth solutions, including coordinating pilot projects. OTI focuses on innovative communication solutions that facilitate better collaboration between doctors, patients, families, and care workers and help patients better understand and adhere to their care plans. With its partners, OTI offers lightweight, highly accessible technology solutions including web and video conferencing, document management, and automated voice solutions. OTI also provides best practices consulting and telehealth readiness assessments.

CareMeeting was formed to address a critical problem in healthcare - the need for better communication and collaboration between doctors, patients, family members, and care workers. In particular, CareMeeting provides interactive telehealth tools for patient-centric care. The tools include a distributed cloud platform for concurrent participation including by voice, video, text, document and image sharing. Other tools are interactive voice response (IVR) to utilize phones for communication, medication reminders, and data collection, as well as survey and other applications that enable everyone to participate in achieving good patient outcomes, wellness, and efficient high quality, affordable care. CareMeeting also works with the Ohio Telehealth Initiative.

Signet Accel provides the collaborative healthcare analytics platform for clinical practice and biomedical and translational research. The Accelematics™ product is a distributed (decentralized) patient disease registry solution that enables each organization (hospitals, research centers, biopharma companies, CRO’s, etc.) to securely share and analyze data with authorized collaborators while maintaining full ownership and control over their own repositories. The technology was developed at The Ohio State University and has been successfully deployed in federated multi-site commercial projects. Signet Accel’s solution and services are designed to eliminate barriers and boundaries for collaboration and data utilization by unifying geographically separated systems and integrating silos of clinical and biomedical information, including EHR data, Biospecimen and clinical trials information, medical practice and quality improvement data, meaningful use reports, drug safety, translational research data, and population- and disease-specific data. I participated in commercialization and formation of this rapidly growing company and developed the business plan.Jeff was "Employee Number 1" at Signet Accel and serves as its Chief Science Officer, where he provides business and technology management. Dr. Spitzner was a co-leader on the 2003 grant that funded the initial development of the technology at Ohio State (for Rescentris in the $6 Million Public-Private Partnership). In 2012-13, Jeff built relationships with the OSU research leadership (inventors) and the OSU Technology Commercialization Office, identified this as ready to spin out, and brought in Signet Enterprises as the investment group to fund the deal and form the company. Spitzner also continues to perform due diligence on potential future investments for Signet.

Signet Ventures is the M&A and investment arm of Signet Enterprises, which includes Signet International, Signet Capital (investment bank, debt financing, financial services), and Signet Development – which provides full service financing, development and management services, and specializes in innovative public-private partnerships. Signet currently manages over $3 Billion in financed projects, many in the healthcare space. I provided business and technology expertise for new technology ventures including licensing, commercialization, and company formation around healthcare information technology developed at The Ohio State University.

SoftSyl Technologies is a voice technology software firm specializing in cloud-based IVR (Interactive Voice Response) and call center solutions. SoftSyl developed from the ground up an innovative integrated full-function IVR system built by industry experts, using the leading technologies to be: (1) Standards compliant (VoiceXML); (2) Fast, high performance, efficient, and cost-effective; (3) Scalable to fit any call volume; (4) Readily adaptable to changing scripts, workflows, and systems. The SoftSyl IVR platform facilitates customer support and other call center functions with inbound IVR to handle scripted call flows for self-service and intelligent connection to live agents. The outbound functions enable voice broadcast, surveys, appointment reminders and other proactive voice and text message actions.My role as VP is to focus on business strategy, partnerships, and growth in key verticals such as healthcare.

bioWorld is a global supplier of life sciences and biotechnology lab products for research, including affinity chromatography, molecular biology, cell culture and microbiology. The company was founded in 1994 and is headquartered in Dublin, Ohio. bioWorld is a science-driven company.My role as VP was to develop a strategic business growth plan, lead development of innovative high value new lab products and kits for scientific research, implement strategic partnerships, and guide marketing and business development. During my 9 month project there, I led initiatives to: rationalize and structure the product catalog to focus on coherent profitable lines, improve operations, update the website to improve SEO and streamline customer experience, develop new marketing campaigns, bring on new supply chain and distribution partners, train channel partners for sales and marketing strategies, improve financial management, and increased monthly revenues by 40%.

Added chief executive title and role in addition to President and Chief Science Officer. Led successful fundraising efforts and grew customer base to over 100 enterprise sites and 300% increase in sales. Electronic Lab Notebook (ELN) systems were sold to a wide range of pharmaceutical and biotechnology companies, university and non-profit research institutions, government labs, biofuels and energy companies, and other industries.

Rescentris develops electronic lab notebook (ELN) software called CERF for the life sciences and general research industries. CERF is built using leading semantic technologies to manage and share scientific information and lab records. Rescentris partnered with The Ohio State University to receive the State's first Third Frontier grant ($6 Million) to develop and commercialize biomedical software. Jeff served as product and market visionary, business development, fundraising, and strategy leadership, and led equity investment financing of $3 Million.

LabBook developed bioinformatics software, including the Genomic Workspace and the Human Genome Database, and worked to advance the BSML genomics data standard. LabBook worked to develop a desktop environment to deliver content and services to scientists. Technology and products were sold to companies such as Bristol-Myer Squibb, Johnson and Johnson, IBM, Fujitsu, Wiley and Son, Itochu, and other innovative organizations. LabBook licensed innovative technology from the Ohio State University that enabled it to build and release the first commercial integrated human genome database in 2001.

Visual Genomics was a software company that focused on bioinformatics, electronic lab notebooks, and data management solutions for the life sciences research industry. Its founders developed the BSML data standard for genomics in 1997 as the first XML based data standard in life sciences, and the BSML Browser for bioinformatics as one of the first XML based applications.

Commercialized Ph.D. research on DNA Topoisomerase enzymes by developing reagents and kits for drug development and cancer research studies.